Management of Infertility – one function and role as protective agent in prevention and therapy. Abstract Infertility, a couple’s inability to conceive after one year of unprotected regular intercourse, is an important issue in the world. The use of FFV51 in the treatment of infertility is considered as a possible alternative to conventional therapies indicated in case of physical and mental fatigue stress, with beneficial effects on quality of male / female fertility. The present study aimed to investigate the effects and the mechanisms of various natural products on infertility. FFV51 possess antioxidant properties and androgenic activities on productive factors and hormones. Antioxidants are the first defense barrier against free radicals produced by oxidative stress (OS). They remove reactive oxygen stress (ROS), increase endometrial receptivity and fertility ability. Male infertility is associated with increased oxidative stress and low GSH levels. Elevated GSH levels may enhance the quality of sperm and increase fertility. It is an essential nutrient in terms of fertility for both man. Female infertility refers to infertility in women. Infertility can be primary, in women who have never conceived, or secondary, in women who have previously conceived. The most common causes of female infertility include problems with ovulation, damage to fallopian tubes or uterus, or problems with the cervix. Age can contribute to infertility because as a woman ages, her fertility naturally tends to decrease FFV51 can be very effective in re-balancing hormones, as well as improving for the partner's overall health, which are so vital for successful conception. The present review aims to compile available information regarding different natural exogenous factors that demonstrate potential useful activity in the male reproductive system. The studies presented here reopen the perspective of using FFV51 as protective agent as new supplementary therapeutic for the recovery of hampered spermatogenesis and/or male infertility. The same for hampered ovogenesis and/or female infertility.